Vol. 22/No. 12 | OncologyLive

MET Inhibitors Find Their Niche in NSCLC

June 23, 2021

Three-quarters of all cases of lung adenocarcinoma, the most common type of non–small cell lung cancer, are defined by oncogenic driver events involving receptor tyrosine kinase–orchestrated cellular signaling pathways.

Experts Break Down Exciting Breakthroughs in NSCLC

June 22, 2021

Experts in lung cancer discuss advances with targeted therapies in non–small cell lung cancer, highlighting the latest and most pivotal data in the thoracic space and how the data apply to clinical practice.

Garassino Highlights What’s In Store for Lung Cancer

June 21, 2021

Patients with lung cancer were identified as an at-risk group for developing severe complications as a result of SARS-CoV-2 infection, and thoracic oncologists were fast to respond with the establishment of the Thoracic Cancers International COVID-19 Collaboration.

KRAS Pathway Opens Door for Patients With Difficult-to-Treat Ovarian Cancer

June 18, 2021

Clinical Insights

Dual blockade of the RAF/MEK and FAK pathways presents an opportunity for investigators to enhance and expand the number of patients with recurrent low-grade serous ovarian cancer who can benefit from targeted therapies.

Moving Curative Therapies Forward in Hematologic Malignancies

June 17, 2021

Cover Story

Because hematological cancers are rarer than solid tumors, information on treatment practices is somewhat less available, so hematologists are particularly interested in learning what their peers are doing.

Precision Medicine Presents a Disconnect in Oncology Practice

June 16, 2021

Multiple FDA approvals and an increasing number of clinical trials examining molecular target–based therapeutics, including second- or even third-generation drugs against a well-defined target, present an ever-widening array of drugs for routine cancer care based on the discovery of specific molecular targets within the tumor or within the germline.